The price-to-earnings ratio for Acadia Pharmaceuticals Inc (NASDAQ: ACAD) is above average at 12.15x, Company’s 36-month beta value is 0.47.Analysts have differing opinions on the stock, with 6 analysts rating it as a “buy,” 6 as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for ACAD is 166.03M, and currently, short sellers hold a 9.23% ratio of that floaft. The average trading volume of ACAD on May 08, 2025 was 1.74M shares.
ACAD) stock’s latest price update
The stock price of Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has jumped by 12.46 compared to previous close of 14.81. Despite this, the company has seen a gain of 14.31% in its stock price over the last five trading days. seekingalpha.com reported 2025-05-07 that ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Al Kildani – SVP of IR & Corporate Communications Catherine Owen Adams – CEO Tom Garner – COO Elizabeth Thompson – EVP and Head of R&D Mark Schneyer – EVP and CFO Conference Call Participants Ritu Baral – TD Cowen Tessa Romero – JPMorgan Ash Verma – UBS Elaine Kim – Canter Basma Radwan – Leerink Partners David Huang – Deutsche Bank Tazeen Ahmad – Bank of America Yatin Suneja – Guggenheim Joel Beatty – Baird Sumant Kulkarni – Canaccord Genuity Malcolm Hoffman – BMO Capital Markets Operator Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals Conference Call. My name is Lauren Cannon, and I’ll be your coordinator for today.
ACAD’s Market Performance
Acadia Pharmaceuticals Inc (ACAD) has experienced a 14.31% rise in stock performance for the past week, with a 18.12% rise in the past month, and a -12.94% drop in the past quarter. The volatility ratio for the week is 3.73%, and the volatility levels for the past 30 days are at 4.69% for ACAD.. The simple moving average for the past 20 days is 12.89% for ACAD’s stock, with a -0.13% simple moving average for the past 200 days.
Analysts’ Opinion of ACAD
Many brokerage firms have already submitted their reports for ACAD stocks, with Deutsche Bank repeating the rating for ACAD by listing it as a “Hold.” The predicted price for ACAD in the upcoming period, according to Deutsche Bank is $22 based on the research report published on February 11, 2025 of the current year 2025.
Guggenheim, on the other hand, stated in their research note that they expect to see ACAD reach a price target of $20, previously predicting the price at $23. The rating they have provided for ACAD stocks is “Neutral” according to the report published on January 03rd, 2025.
ACAD Trading at 3.42% from the 50-Day Moving Average
After a stumble in the market that brought ACAD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.46% of loss for the given period.
Volatility was left at 4.69%, however, over the last 30 days, the volatility rate increased by 3.73%, as shares surge +11.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.08% lower at present.
During the last 5 trading sessions, ACAD rose by +14.65%, which changed the moving average for the period of 200-days by -7.86% in comparison to the 20-day moving average, which settled at $14.76. In addition, Acadia Pharmaceuticals Inc saw -9.24% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACAD starting from Kihara James, who sale 1,327 shares at the price of $14.60 back on May 02 ’25. After this action, Kihara James now owns 23,526 shares of Acadia Pharmaceuticals Inc, valued at $19,374 using the latest closing price.
Schneyer Mark C., the EVP, CHIEF FINANCIAL OFFICER of Acadia Pharmaceuticals Inc, sale 3,498 shares at $14.60 during a trade that took place back on May 02 ’25, which means that Schneyer Mark C. is holding 62,773 shares at $51,071 based on the most recent closing price.
Stock Fundamentals for ACAD
Current profitability levels for the company are sitting at:
- 0.24 for the present operating margin
- 0.91 for the gross margin
The net margin for Acadia Pharmaceuticals Inc stands at 0.24. The total capital return value is set at 0.29. Equity return is now at value 37.24, with 23.03 for asset returns.
Based on Acadia Pharmaceuticals Inc (ACAD), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at 3.03.
Currently, EBITDA for the company is 100.16 million with net debt to EBITDA at -2.74. When we switch over and look at the enterprise to sales, we see a ratio of 2.62. The receivables turnover for the company is 9.15for trailing twelve months and the total asset turnover is 0.81. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.88.
Conclusion
In a nutshell, Acadia Pharmaceuticals Inc (ACAD) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
